Skip to main content
SpringerLink
Log in

Die neue S3-Leitlinie „Melanom“

Das Wichtigste für die Praxis

  • Topic
  • S3-Leitlinie Melanom
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Das kutane Melanom ist der Hauttumor mit der höchsten Metastasierungsrate und zählt zu den häufigsten soliden Tumoren. Die Inzidenz ist steigend. Nachdem die Therapieoptionen jahrelang stark limitiert waren, eröffnen sich dank des Forschungsfortschritts der letzten Jahre neue Optionen für zielgerichtete oder immunmodulatorische Therapien für Patienten im fortgeschrittenen Tumorstadium. Die neue S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms, veröffentlicht im Januar dieses Jahres, bietet eine Entscheidungshilfe für dermatologisch und onkologisch tätige Ärzte in Praxis und Klinik. Ziel ist es, Qualitätsstandards zu setzen und damit langfristig die Versorgung von Melanompatienten verbessern.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bafounta ML, Beauchet A, Aegerter P et al (2001) Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 137:1343–1350

    Article  CAS  Google Scholar 

  2. Kittler H, Pehamberger H, Wolff K et al (2002) Diagnostic accuracy of dermoscopy. Lancet Oncol 3:159–165

    Article  CAS  Google Scholar 

  3. Tronnier M, Garbe C, Brocker EB et al (1997) Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society. Hautarzt 48:720–729

    Article  CAS  Google Scholar 

  4. Pflugfelder A, Weide B, Eigentler TK et al (2010) Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol 28:316–318

    Article  Google Scholar 

  5. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206

    Article  Google Scholar 

  6. Valsecchi ME, Silbermins D, Rosa N de et al (2011) Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol

    Google Scholar 

  7. Warycha MA, Zakrzewski J, Ni Q et al (2009) Meta-analysis of sentinel lymph node positivity in thin melanoma (< or=1 mm). Cancer 115:869–879

    Article  Google Scholar 

  8. McMasters KM, Wong SL, Edwards MJ et al (2001) Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 130:151–156

    Article  CAS  Google Scholar 

  9. Bafounta ML, Beauchet A, Chagnon S et al (2004) Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol 5:673–680

    Article  Google Scholar 

  10. Brand CU, Ellwanger U, Stroebel W et al (1997) Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 79:2345–2353

    Article  CAS  Google Scholar 

  11. Sanki A, Scolyer RA, Thompson JF (2009) Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 35:313–319

    Article  CAS  Google Scholar 

  12. Yancovitz M, Finelt N, Warycha MA et al (2007) Role of radiologic imaging at the time of initial diagnosis of stage T1b–T3b melanoma. Cancer 110:1107–1114

    Article  Google Scholar 

  13. Vereecken P, Laporte M, Petein M et al (2005) Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol 19:66–73

    Article  CAS  Google Scholar 

  14. Xing Y, Bronstein Y, Ross MI et al (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 19(103):129–142

    Article  Google Scholar 

  15. Sawyer A, McGoldrick RB, Mackey SP et al (2009)Does staging computered tomography change management in thick malignant melanoma? J Plast Reconstr Aesthet Surg 62:453–456

    Article  Google Scholar 

  16. Tsao H, Feldman M, Fullerton JE et al (2004) Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 140:67–70

    PubMed  Google Scholar 

  17. Hofmann U, Szedlak M, Rittgen W et al (2002) Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 87:151–157

    Article  CAS  Google Scholar 

  18. Mocellin S, Zavagno G, Nitti D (2008) The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 123:2370–2376

    Article  CAS  Google Scholar 

  19. Kleeberg UR, Tews JT, Ruprecht T et al (2005) Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 13:303–310

    Article  CAS  Google Scholar 

  20. Fallowfield L, Jenkins V, Farewell V et al (2002) Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial. Lancet 359:650–656

    Article  Google Scholar 

  21. Gysels M, Richardson A, Higginson IJ (2004) Communication training for health professionals who care for patients with cancer: a systematic review of effectiveness. Support Care Cancer 12:692–700

    Article  Google Scholar 

  22. Lehmann C, Koch U, Mehnert A (2009) Impact of the doctor-patient-communication on distress and utilization of psychosocial services among cancer patients. A review of the current literature. Psychother Psychosom Med Psychol 59:e3–e27

    Article  Google Scholar 

  23. Sladden MJ, Balch C, Barzilai DA et al (2009) Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 4:CD004835

    Google Scholar 

  24. Pflugfelder A, Kochs C, Garbe C et al (2013) S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms. http://www.leitlinienprogramm-onkologie.de/Leitlinien.7.0.html

    Google Scholar 

  25. Loser C, Rompel R, Breuninger H et al (2010) Microscopically controlled surgery (MCS). J Dtsch Dermatol Ges 8:920–925

    PubMed  Google Scholar 

  26. Lichte V, Breuninger H, Metzler G et al (2009) Acral lentiginous melanoma: conventional histology vs. three-dimensional histology. Br J Dermatol 160:591–599

    Article  CAS  Google Scholar 

  27. Weide B, Derhovanessian E, Pflugfelder A et al (2010) High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116:4139–4146

    Article  CAS  Google Scholar 

  28. Moreno-Ramirez D, Cruz-Merino L, Ferrandiz L et al (2010) Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 15:416–427

    Article  Google Scholar 

  29. Burmeister BH, Henderson MA, Ainslie J et al (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 13:589–597

    Article  Google Scholar 

  30. Garbe C, Eigentler TK, Keilholz U et al (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5–24

    Article  CAS  Google Scholar 

  31. Mocellin S, Pasquali S, Rossi CR et al (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493–501

    Article  CAS  Google Scholar 

  32. Leo F, Cagini L, Rocmans P et al (2000) Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 83:569–572

    Article  CAS  Google Scholar 

  33. Avril MF, Aamdal S, Grob JJ et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125

    Article  CAS  Google Scholar 

  34. Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166

    Article  CAS  Google Scholar 

  35. Patel PM, Suciu S, Mortier L et al (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47:1476–1483

    Article  CAS  Google Scholar 

  36. Eigentler TK, Caroli UM, Radny P et al (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748–759

    Article  CAS  Google Scholar 

  37. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  CAS  Google Scholar 

  38. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516

    Article  CAS  Google Scholar 

  39. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  CAS  Google Scholar 

  40. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526

    Article  CAS  Google Scholar 

  41. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al (1999) Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 44:607–618

    Article  CAS  Google Scholar 

  42. Romano E, Scordo M, Dusza SW et al (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28:3042–3047

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122, Essen, Deutschland

    Dr. C. Kochs & D. Schadendorf

  2. Zentrum für Dermatologische Onkologie, Universitäts-Hautklinik Tübingen, Tübingen, Deutschland

    A. Pflugfelder & C. Garbe

Authors
  1. Dr. C. Kochs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Pflugfelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Schadendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dr. C. Kochs.

Additional information

Die Autoren C. Kochs und A. Pflugfelder haben gleichermaßen zum Artikel beigetragen.

Interessenkonflikt

Es wird auf folgende Beziehungen hingewiesen: A. Pflugfelder hat ein Beraterhonorar der Firma Bristol-Myers Squibb erhalten. D. Schadendorf: Beratungstätigkeiten und Vorträge für Roche, GSK, BMS, Amgen, MSD; Beratungstätigkeiten für Novartis; Reisekostenübernahme von Roche, BMS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kochs, D.C., Pflugfelder, A., Garbe, C. et al. Die neue S3-Leitlinie „Melanom“. best practice onkologie 8, 40–48 (2013). https://doi.org/10.1007/s11654-013-0044-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-013-0044-2

Search

Navigation